Yahoo Web Search

  1. AbbVie and Allergan said they still expect the deal to close in early 2020, and were cooperating with the antitrust regulator. The scrutiny into the deal, which combines two of the world's ...

  2. Five drugmakers battling the cases - Endo, J&J, Teva Pharmaceutical Industries Ltd , Allergan Plc and Mallinckrodt Plc - are looking to enact a global settlement of the ...

  3. Allergan (AGN) Stock Moves -1.09%: What You Should Know

    Zacks via Yahoo FinanceOct 01 21:50 PM

    Allergan (AGN) closed the most recent trading day at $166.46, moving -1.09% from the previous trading session. In that same time, the Medical sector lost 1.2%, while the S&P 500 gained ...

  4. Allergan (AGN) Stock Moves -0.1%: What You Should Know

    Zacks via Yahoo FinanceSep 24 21:50 PM

    This change was narrower than the S&P 500's daily loss of 0.84%. Heading into today, shares of the Botox maker had gained 4.14% over the past month, outpacing the Medical sector's gain of 2.64% ...

  5. AbbVie will extract significant shareholder value from its proposed Allergan plc (NYSE: AGN) acquisition, given its "industry-leading commercial focus and patient/physician centricity ...

  6. Here Is Hedge Funds’ 22nd Most Popular Stock Pick

    Insider Monkey via Yahoo FinanceOct 03 21:30 PM

    Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. A particularly interesting group of stocks ...

  7. We remind investors that, Allergan plc’s AGN NDA for oral anti-calcitonin gene-related peptide (“CGRP”) candidate, ubrogepant is under review by the FDA for the acute treatment ...

  8. The lead compound ANAVEX 2-73, generically blarcamesine, is being developed for Alzheimer's, Parkinson's disease and other central nervous system diseases, including rare diseases such as Rett ...

  9. Stocks recently featured in the blog include: Bristol-Myers Squibb BMY, Lockheed Martin LMT, Alphabet GOOGL, Allergan AGN and Kinder Morgan KMI.

  10. J&J became the fourth drugmaker to settle claims ahead of the Federal Court trial against multiple manufacturers and distributors in Cleveland scheduled for later this month. "The settlement ...